Gastrointestinal Disorders in Scleroderma.

Gastrointestinal involvement affects up to 90% of systemic sclerosis patients, causing diverse symptoms from esophageal dysphagia to colonic dilation.

• Why it matters: Understanding GI manifestations in scleroderma is crucial because they significantly impact patient quality of life and are linked to complex pathogenic features like vasculopathy and fibrosis, yet evidence-based treatments are limited.
• What they did: The study reviews the clinical features, underlying mechanisms, and challenges in managing GI symptoms in systemic sclerosis, emphasizing the variability and poor symptom-pathology correlation.
• The result: Findings highlight the need for tailored, vigilant care by gastroenterologists and underscore the importance of further research to develop effective, disease-specific therapies for GI complications in scleroderma.